Australia markets closed

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
108.69+2.42 (+2.28%)
At close: 4:02PM EST

108.66 -0.03 (-0.03%)
Pre-market: 6:27AM EST

Full screen
Trade prices are not sourced from all markets
Previous close106.27
Open106.00
Bid107.51 x 1200
Ask109.88 x 1100
Day's range105.60 - 109.44
52-week range62.55 - 113.41
Volume6,594,042
Avg. volume7,363,890
Market cap191.934B
Beta (5Y monthly)0.81
PE ratio (TTM)39.96
EPS (TTM)2.72
Earnings date29 Apr 2021 - 03 May 2021
Forward dividend & yield5.20 (4.78%)
Ex-dividend date14 Apr 2021
1y target est120.67
  • HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
    PR Newswire

    HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis

    AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. In clinical trials, HUMIRA induced clinical remission at Week 8 and maintained remission at Week 52 in patients who responded at Week 8.1,2

  • New REFRESH® DIGITAL Lubricant Eye Drops Tackle Eye Dryness Due to Everyday Screen Use
    PR Newswire

    New REFRESH® DIGITAL Lubricant Eye Drops Tackle Eye Dryness Due to Everyday Screen Use

    From scrolling through social media feeds, to video conferences for work and school, to relaxing with television and video games, Americans are spending approximately 13 hours a day on some type of digital device.1 As the reliance on screens to connect digitally for both professional and personal use continues to rise, more than half of adults suffer from digital eye strain,2 which often includes dry, irritated eyes.

  • 2 Best Pharma Stocks to Buy Right Now
    Motley Fool

    2 Best Pharma Stocks to Buy Right Now

    Regeneron Pharmaceuticals (NASDAQ: REGN) and AbbVie (NYSE: ABBV) have managed to deliver strong fourth quarter earnings. Regeneron Pharmaceuticals' fiscal 2020 performance has been quite remarkable, considering the many pressures it faced due to COVID-19 related restrictions. Regeneron's blockbuster retinal disease drug, EYLEA, continues to be a force to reckon with, clocking sales of $7.9 billion globally (in conjucnction with Bayer).